COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio
Dr. Falk Pharma GmbH acquires Kynos Therapeutics Ltd., focusing on inflammatory disease treatments. KNS366, a novel enzyme inhibitor, shows promise in clinical trials for acute pancreatitis -
COMMUNIQUÉ DE PRESSE
Magna Terra Stakes the 8 KM Long Hughes Lake Copper-Cobalt Trend at the Humber Project and Increases Property Size by 23%
Magna Terra Minerals Inc. expands Humber Copper-Cobalt Project by 23% with acquisition of Hughes Lake Trend. Project focuses on critical minerals & metals exploration in Newfoundland. First mover advantage in mining sector -
-
-
COMMUNIQUÉ DE PRESSE
Sterling Metals Provides Exploration Update for Copper Road, Including up to 15.9% Copper and 4.84% Molybdenum in Surface Grab Samples
Sterling Metals Corp. provides exploration update on high-potential Copper Road Project in Ontario, Canada. Discoveries include high-grade copper, molybdenum, gold, and silver mineralization -
COMMUNIQUÉ DE PRESSE
Beyond Oil Expands Sales into Eastern Europe with 16 Ton Order from Franchisee of Global Fast-Food Chain
Beyond Oil announces major milestone in expanding global commercialization efforts with an order from a European fast-food chain, representing a significant step in disrupting the food oil industry worldwide -
COMMUNIQUÉ DE PRESSE
Northern Superior Reports 2.60 g/t Au Over 26.5 Metres Including 4.55 g/t Au Over 13.4 Metres, From Its Resource Expansion Drilling Program at Philibert
Northern Superior Resources Inc. announces positive results from the expansion drilling campaign at the Philibert gold property near Chibougamau, Quebec. Significant mineralized intersections confirm potential resource expansion -
COMMUNIQUÉ DE PRESSE
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
Quantum BioPharma starts sentinel dosing for Lucid-21-302 trial in multiple sclerosis treatment. Corporate update includes engaging ITG, Buyins, and Stockjock for Investor Relations Activities -
